Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrograde endoscopic submucosal dissection for early thoracic esophageal carcinoma.
Kobayashi Y, Nishikawa K, Akasaka T, Kato S, Hamakawa T, Yamamoto K, Kobayashi N, Kitakaze M, Maeda S, Uemura M, Miyake M, Hama N, Miyamoto A, Kato T, Miyazaki M, Nakamori S, Mita E, Sekimoto M, Mano M, Hirao M. Kobayashi Y, et al. Among authors: kato t, kato s. Clin J Gastroenterol. 2021 Apr;14(2):434-438. doi: 10.1007/s12328-021-01371-0. Epub 2021 Mar 10. Clin J Gastroenterol. 2021. PMID: 33689125
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: kato s. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433. doi: 10.1111/apt.16691. Epub 2021 Nov 23. Aliment Pharmacol Ther. 2022. PMID: 34812502 Clinical Trial.
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: kato s. Aliment Pharmacol Ther. 2022 Apr;55(8):1061-1062. doi: 10.1111/apt.16862. Aliment Pharmacol Ther. 2022. PMID: 35362133 No abstract available.
STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
Makino Y, Hikita H, Kato S, Sugiyama M, Shigekawa M, Sakamoto T, Sasaki Y, Murai K, Sakane S, Kodama T, Sakamori R, Kobayashi S, Eguchi H, Takemura N, Kokudo N, Yokoi H, Mukoyama M, Tatsumi T, Takehara T. Makino Y, et al. Among authors: kato s. Cell Mol Gastroenterol Hepatol. 2023;15(1):99-119. doi: 10.1016/j.jcmgh.2022.09.006. Epub 2022 Sep 20. Cell Mol Gastroenterol Hepatol. 2023. PMID: 36210625 Free PMC article.
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis.
Sato K, Hikita H, Shigekawa M, Soma K, Yamauchi R, Sung J, Kato S, Sasaki Y, Kudo S, Fukumoto K, Shirai K, Murai K, Tahata Y, Yoshioka T, Nishio A, Saito Y, Kodama T, Sasaki Y, Tatsumi T, Takehara T. Sato K, et al. Among authors: kato s. Sci Rep. 2024 May 26;14(1):12028. doi: 10.1038/s41598-024-62498-x. Sci Rep. 2024. PMID: 38797735 Free PMC article.
Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss.
Sato K, Hikita H, Shigekawa M, Kato S, Sasaki Y, Shinkai K, Fukuoka M, Kudo S, Sato Y, Fukumoto K, Shirai K, Myojin Y, Sakane S, Murai K, Yoshioka T, Nishio A, Kodama T, Sakamori R, Tatsumi T, Takehara T. Sato K, et al. Among authors: kato s. Cancer Sci. 2022 Dec;113(12):4311-4326. doi: 10.1111/cas.15569. Epub 2022 Oct 12. Cancer Sci. 2022. PMID: 36074525 Free PMC article.
7,164 results